MS-10 thistle complex,
does it really help with Relief of menopausal symptoms in women?
research showsMS-10 is a branded combination of Korean thistle and thyme. Trials with 30 participants, 151 randomized and 142 completing, and 71 participants were positive, but all came from the Noh/Famenity MS-10 development network and are not independent replications. Recognition No. 2020-6 establishes trial existence only, leaving this single branded combination at C.
ads claimMarketing may bundle menopause relief with bone health, hormone balance, and anti-aging. Direct evidence concerns short-term symptom scales for a specific MS-10 formulation and does not establish replacement of hormone therapy or fracture prevention.
Useful facts when choosing a product
- MS-10 is a branded combination of Cirsium japonicum var. maackii and Thymus vulgaris extracts.
- The labeled daily intake for the individually recognized MS-10 ingredient in South Korea is 300 mg/day.
- Korean combination products, including Repiera, may contain other functional ingredients, so the perceived effect of the finished product cannot be isolated to MS-10.
- Trials used 300 or 500 mg/day for 90 days or 12 weeks.
What the research actually shows
The 2016 Noh trial with 30 participants, the 2019 trial randomizing 151 and retaining 142, and the 2022 trial with 71 participants reported positive Kupperman Index and MenQoL findings. All three reports, however, come from the Noh/Famenity MS-10 development network studying the same branded combination and cannot be counted as independent replications. MFDS individual recognition No. 2020-6 establishes that a trial dossier exists but is not itself independent efficacy replication.
Why this is classified as C (50)
Positive reports with n=30, 142 completers, and n=71 all come from the Noh/Famenity MS-10 development network, study one branded combination, emphasize subjective scales, and lack independent replication. Recognition No. 2020-6 establishes trial existence only, resulting in C with 50 points.
Counterpoint. A 12-week symptom-scale signal remains for the exact MS-10 formulation at 300 to 500 mg/day.
Rejudgment record. Reassessment (cross-check reflected) — Positive reports with n=30, 142 completers, and n=71 all belong to the Noh/Famenity MS-10 development network for one branded combination; recognition No. 2020-6 establishes trial existence only and independent replication is absent
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Noh YH et al. 2016 | Randomized controlled clinical trial | 90 | Included Famenity-affiliated authors and public research support | Twelve Kupperman symptoms and vaginal dryness | Reported improvement in menopausal symptoms and vaginal dryness with MS-10 at 300 and 500 mg/day versus placebo. | Supportive, developer-linked |
| Noh YH et al. 2019 | Randomized placebo-controlled clinical trial | 12 | MS-10 development network | MenQoL, alkaline phosphatase, and osteocalcin | Reported improved MenQoL and changes in bone-turnover markers with MS-10 at 500 mg/day. | Key, overlapping research network |
| Noh YH et al. 2022 | Randomized double-blind placebo-controlled trial | 12 | Authors linked to the MS-10 developer | Kupperman Index, MenQoL, and blood and bone-turnover markers | Reported approximately 48% improvement in the Kupperman Index and 36% improvement in MenQoL. | Key, developer-linked |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-15).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-15 · Corrections: none
Cite this verdict
[Chamgap] MS-10 thistle complex × Relief of menopausal symptoms in women — Evidence Grade C·50. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/womens/ms-10-thistle-complex/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.